Change from baseline in LCI for patients with FEV1 >60% pred values at screening after 4 weeks of treatment | Percentage of patients with treatment-emergent AEs up to day 36 | Concentration of the analyte in plasma at time t following dose N (Ct.N) |
Change from baseline in CFQ-R after 4 weeks of treatment | | Pre-dose concentration measured for dose N (Cpre.N) |
Change from baseline in CASA-Q after 4 weeks of treatment | | Area under the concentration–time curve of the analyte in plasma until t hours after dose N (AUC0–t,N) |